Short Interest in Genprex, Inc. (NASDAQ:GNPX) Rises By 5.2%

Genprex, Inc. (NASDAQ:GNPX) saw a significant increase in short interest during the month of October. As of October 15th, there was short interest totalling 85,200 shares, an increase of 5.2% from the September 30th total of 81,000 shares. Approximately 3.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 8,350,000 shares, the short-interest ratio is currently 0.0 days.

Hedge Funds Weigh In On Genprex

An institutional investor recently raised its position in Genprex stock. Armistice Capital LLC lifted its stake in shares of Genprex, Inc. (NASDAQ:GNPX) by 122.7% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 218,000 shares of the company’s stock after purchasing an additional 120,132 shares during the period. Armistice Capital LLC owned 10.39% of Genprex worth $411,000 as of its most recent SEC filing. Institutional investors own 14.05% of the company’s stock.

Genprex Price Performance

Shares of Genprex stock opened at $2.15 on Friday. Genprex has a 12 month low of $0.28 and a 12 month high of $14.80. The stock has a 50 day moving average of $0.79 and a 200 day moving average of $1.59.

Genprex (NASDAQ:GNPX) last announced its earnings results on Friday, August 9th. The company reported ($3.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.30) by ($0.70). As a group, analysts forecast that Genprex will post -5.7 earnings per share for the current fiscal year.

About Genprex

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.